COMPUGEN LTD CGEN
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.38
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.8M | $27.9M | $33.5M | $7.5M | $6.0M | $2.0M | — | $17.8M | — | $400.0K |
| Cost of revenue | $9.3M | $7.9M | $2.0M | $975.0K | $680.0K | $60.0K | — | $1.0M | — | $223.0K |
| Gross profit | $63.5M | $19.9M | $31.5M | $6.5M | $5.3M | $1.9M | — | $16.8M | — | $489.0K |
| R&D | $22.8M | $24.8M | $34.5M | $30.6M | $28.7M | $22.8M | $19.8M | $30.3M | $28.6M | $24.5M |
| SG&A | $8.9M | $9.4M | $9.7M | $10.3M | $10.9M | $9.8M | $8.4M | $8.0M | $7.6M | $7.3M |
| Total operating expenses | $32.2M | $34.8M | $44.4M | $41.9M | $40.4M | $33.4M | $28.9M | $40.0M | $37.4M | $33.1M |
| Operating income | $31.3M | -$14.9M | -$13.0M | -$35.4M | -$35.1M | -$31.5M | -$28.9M | -$23.2M | -$37.4M | -$32.6M |
| Pre-tax income | $35.4M | -$9.7M | -$9.8M | -$33.6M | -$34.2M | -$29.7M | -$28.1M | -$22.6M | -$37.1M | -$31.5M |
| Income tax | $54.0K | $4.5M | $9.0M | $58.0K | $0 | $0 | $722.0K | — | — | $20.0K |
| Net income | $35.3M | -$14.2M | -$18.8M | -$33.7M | -$34.2M | -$29.7M | -$27.3M | -$22.6M | -$37.1M | -$31.5M |
| EPS, basic | 0.38 | -0.16 | -0.21 | -0.39 | -0.41 | -0.37 | -0.43 | -0.41 | -0.72 | -0.62 |
| EPS, diluted | 0.38 | -0.16 | -0.21 | -0.39 | -0.41 | -0.37 | -0.43 | -0.41 | -0.72 | -0.62 |
| Shares, diluted (wtd. avg.) | 93.8M | 89.5M | 87.6M | 86.6M | 84.2M | 79.6M | 63.6M | 55.3M | 51.2M | 50.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $90.6M | $18.2M | $13.9M | $11.4M | $8.5M | $7.8M | $9.8M | $6.5M | $26.5M | $10.7M |
| Short-term investments | $9.3M | $23.6M | $11.7M | $0 | — | — | — | — | — | — |
| Receivables | — | $0 | $61.0M | $0 | — | $2.0M | — | — | — | — |
| Total current assets | $148.0M | $106.0M | $114.6M | $86.1M | $123.2M | $129.1M | $45.0M | $46.6M | $31.2M | $62.7M |
| Property, plant and equipment | $681.0K | $852.0K | $1.2M | $1.5M | $1.7M | $1.7M | $2.3M | $3.4M | $4.6M | $6.0M |
| Total assets | $156.6M | $115.0M | $121.3M | $94.2M | $132.2M | $138.3M | $53.8M | $53.2M | $38.7M | $71.1M |
| Accounts payable | $2.4M | $1.8M | $3.5M | $1.8M | $4.6M | $1.4M | $1.1M | $2.9M | $3.4M | $1.3M |
| Total current liabilities | $22.6M | $20.2M | $26.3M | $11.9M | $17.1M | $10.5M | $6.8M | $10.0M | $6.2M | $4.7M |
| Retained earnings | -$453.4M | -$488.8M | -$474.5M | -$455.8M | -$422.1M | -$387.9M | -$358.2M | -$330.8M | -$308.2M | -$271.0M |
| Total equity | $102.7M | $54.9M | $65.6M | $77.7M | $106.7M | $119.8M | $38.3M | $37.2M | $29.3M | $63.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $31.6M | $49.6M | -$35.9M | -$34.1M | -$22.7M | -$28.3M | -$27.9M | -$13.3M | -$30.7M | -$19.8M |
| Depreciation and amortisation | $475.0K | $486.0K | $476.0K | $482.0K | $461.0K | $715.0K | $989.0K | $1.4M | $1.6M | $1.5M |
| Stock-based compensation | $1.9M | $3.0M | $3.5M | $4.3M | $4.3M | $2.8M | $2.4M | $2.2M | $2.6M | $3.1M |
| Capital expenditure | $306.0K | $118.0K | $172.0K | $477.0K | $292.0K | $166.0K | $155.0K | $158.0K | $385.0K | $2.6M |
| Investing cash flow | $30.0M | -$46.3M | $35.5M | $37.1M | $6.6M | -$82.2M | $5.3M | -$35.2M | $46.3M | $16.2M |
| Financing cash flow | $10.6M | $554.0K | $3.1M | $353.0K | $16.8M | $108.5M | $25.9M | $28.4M | $201.0K | $2.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-000663.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $400.0K | — | $17.8M | — | $2.0M | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Gross profit | $489.0K | — | $16.8M | — | $1.9M | $5.3M | $6.5M | $31.5M | $19.9M | $63.5M |
| Net income | -$31.5M | -$37.1M | -$22.6M | -$27.3M | -$29.7M | -$34.2M | -$33.7M | -$18.8M | -$14.2M | $35.3M |
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |